List of Savaysa drug patents

Savaysa is owned by Daiichi Sankyo Inc.

Savaysa contains Edoxaban Tosylate.

Savaysa has a total of 2 drug patents out of which 0 drug patents have expired.

Savaysa was authorised for market use on 08 January, 2015.

Savaysa is available in tablet;oral dosage forms.

The generics of Savaysa are possible to be released after 28 March, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7365205 DAIICHI SANKYO INC Diamine derivatives
Apr, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9149532 DAIICHI SANKYO INC Pharmaceutical composition
Mar, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
M Aug 9, 2022

Drugs and Companies using EDOXABAN TOSYLATE ingredient

Market Authorisation Date: 08 January, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of SAVAYSA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in